Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia
Introduction: Treatment resistant schizophrenia (TRS), affecting approximately one-third of patients with schizophrenia, is associated with a serious impairment in global psychosocial functioning. Clozapine is the only licensed drug for TRS. However its prescription remains limited by its side effec...
Enregistré dans:
Auteurs principaux: | Amina Aissa, Rahma Jouini, Uta Ouali, Yosra Zgueb, Fethi Nacef, Zouhaier El Hechmi |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2022
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/7feafd787a884556b7db28dda7fe9cc6 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Reduction in Absolute Neutrophil Counts in Patient on Clozapine Infected with COVID-19
par: Fitri Fareez Ramli, et autres
Publié: (2021) -
A survey of personnel and services offered in 32 outpatient US clozapine clinics
par: Robert O. Cotes, et autres
Publié: (2021) -
Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile
par: de Filippis R, et autres
Publié: (2021) -
Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia
par: Cheng MF, et autres
Publié: (2016) -
A case of improvement of clozapine-induced low leukocyte counts by adenine, cepharanthin and ninjin-yoei-to in a patient with treatment-resistant schizophrenia
par: Shintaro Kamei, et autres
Publié: (2021)